In support of this hypothesis, GWASs using CSF levels of the hallmark biomarkers of AD (i.e. amyloid beta and tau) have identified a handful of genetic variants involved also in the susceptibility to AD [93, 182]. The gene discussed is MAPT; the disease is Alzheimer disease.